Sequent Scientific has allotted 5,40,000 equity shares under ESOP on 23 November 2024. With this allotment, the paid up equity share capital has increased to Rs. Rs. 50,06,03,990/-consisting of 25,03,01,995equity shares of Rs. 2/- each.Powered by Capital Market - Live News

Sequent Scientific has completed the acquisition of 3.90% stake from Ms. Katarina Agren in N-VET AB through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. The company also completed the acquisition of 3.75% stake from Renzo Rimondi and 1.25% from Ramon Vila Vina, collectively 5%, in Alivira Italia SRL, through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company.Consequent to the above acquisitions, N-VET AB and Alivira Italia SRL have become Wholly Owned Subsidiaries of the Company.Powered by Capital Market - Live News

Net profit of Sequent Scientific reported to Rs 2.61 crore in the quarter ended September 2024 as against net loss of Rs 8.38 crore during the previous quarter ended September 2023. Sales rose 6.56% to Rs 368.65 crore in the quarter ended September 2024 as against Rs 345.97 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales368.65345.97 7 OPM %10.614.37 - PBDT29.324.20 598 PBT12.22-11.16 LP NP2.61-8.38 LP Powered by Capital Market - Live News

Sequent Scientific has approved the issue and allotment of 120,000 Equity Shares of Rs. 2/- each fully paid to two Employees at an exercise price of Rs. 86/- per equity share on exercise of the options granted to them under SeQuent ESOP 2020. Powered by Capital Market - Live News

Sequent Scientific has allotted 60,000 equity shares under ESOP on 16 October 2024. Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs. 49,91,63,990/-consisting of 249581995 Equity Shares of Rs. 2/- each to Rs. Rs. 49,92,83,990/-consisting of 249641995 Equity Shares of Rs. 2/- each.Powered by Capital Market - Live News